Revance Therapeutics Inc. (NASDAQ: RVNC) stock jumped 8.60% on Friday to $31.70 against a previous-day closing price of $29.19. With 2.8 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.47 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $31.92 whereas the lowest price it dropped to was $29.20. The 52-week range on RVNC shows that it touched its highest point at $30.95 and its lowest point at $11.27 during that stretch. It currently has a 1-year price target of $33.00. Beta for the stock currently stands at 0.66.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RVNC was up-trending over the past week, with a rise of 19.53%, but this was up by 63.15% over a month. Three-month performance surged to 32.64% while six-month performance rose 89.82%. The stock gained 127.89% in the past year, while it has gained 71.72% so far this year. A look at the trailing 12-month EPS for RVNC yields -3.92 with Next year EPS estimates of -3.24. For the next quarter, that number is -1.04. This implies an EPS growth rate of 14.30% for this year and 14.10% for next year. EPS is expected to grow by 11.60% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -5.60%.
Float and Shares Shorts:
At present, 82.27 million RVNC shares are outstanding with a float of 79.47 million shares on hand for trading. On Oct 13, 2022, short shares totaled 9.52 million, which was 11.57% higher than short shares on Sep 14, 2022. In addition to Mr. Mark J. Foley as the firm’s CEO & Director, Mr. Dustin S. Sjuts serves as its Pres.
Through their ownership of 77.78% of RVNC’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 48.84% of RVNC, in contrast to 38.13% held by mutual funds. Shares owned by individuals account for 13.24%. As the largest shareholder in RVNC with 10.29% of the stake, Capital Research & Management Co holds 8,463,909 shares worth 8,463,909. A second-largest stockholder of RVNC, BlackRock Fund Advisors, holds 5,080,816 shares, controlling over 6.18% of the firm’s shares. Polar Capital LLP is the third largest shareholder in RVNC, holding 4,461,747 shares or 5.42% stake. With a 8.00% stake in RVNC, the American Funds Small Cap World Fu is the largest stakeholder. A total of 6,583,932 shares are owned by the mutual fund manager. The Polar Capital Funds Plc – Healthc, which owns about 3.84% of RVNC stock, is the second-largest Mutual Fund holder. It holds 3,158,358 shares valued at 58.3 million. American Funds New Economy Fund holds 3.42% of the stake in RVNC, owning 2,810,000 shares worth 51.87 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RVNC since 13 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RVNC analysts setting a high price target of $65.00 and a low target of $19.00, the average target price over the next 12 months is $33.00. Based on these targets, RVNC could surge 105.05% to reach the target high and fall by -40.06% to reach the target low. Reaching the average price target will result in a growth of 4.1% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. RVNC will report FY 2022 earnings on 02/27/2024. Analysts have provided yearly estimates in a range of -$2.33 being high and -$3.03 being low. For RVNC, this leads to a yearly average estimate of -$2.76. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Revance Therapeutics Inc. surprised analysts by -$0.06 when it reported -$0.85 EPS against a consensus estimate of -$0.79. The surprise factor in the prior quarter was $0.09. Based on analyst estimates, the high estimate for the next quarter is -$0.57 and the low estimate is -$1.58. The average estimate for the next quarter is thus -$0.84.
Summary of Insider Activity:
Insiders traded RVNC stock several times over the past three months with 0 Buys and 2 Sells. In these transactions, 0 shares were bought while 4,473 shares were sold. The number of buy transactions has increased to 7 while that of sell transactions has risen to 17 over the past year. The total number of shares bought during that period was 27,201 while 91,988 shares were sold.